Comprehensive Therapy to Manage PCOS


COMPOSITION: Myo-inositol USP 600 mg + Metformin Hydrochloride IP 500 mg (As Sustained Release)

  • PCOS is the most common endocrine disorder among women between 18 to 44 yrs. 36% of women in India suffer from PCOS. Insulin resistance is a primary cause of PCOS.


  • PCOS






  • Drug class: Insulin-sensitizing agent
  • Leads to a decrease in testosterone, triglycerides, and blood pressure.
  • Significant improvement in insulin Sensitivity.
  • Greatly increased pregnancy of ovulation.
  • Myo-inositol decreases both insulin and BMI.
  • 50% of 92 PCOS patients exhibited significant weight loss and reduced leptin levels with inositol.


  • Drug class: Drug class: Biguanides
  • Decreases the level of androgens produced by ovaries & adrenal glands
  • Helps regulate menstrual cycles, starts ovulation, and leaves the risk of miscarriage in PCOS.
  • Also works for women with PCOS who are unresponsive to clomiphene.